Andrx Enters Into New Development Agreement With Bayer.

FORT LAUDERDALE, Fla.--(BW HealthWire)--March 25, 1999--ANDRX CORPORATION (Nasdaq:ADRX) today announced that it has entered into another agreement with an affiliate of Bayer Corporation to develop a new product. This is the second collaboration between the parties applying Andrx' drug delivery technologies to the Bayer affiliate's over-the-counter (OTC) product creating a controlled-release version of that product.

Commenting on the agreement, Elliot F. Hahn, Ph.D., President of Andrx said, "Eighteen months ago we announced our collaboration with Bayer to develop an OTC product. This new venture confirms the scientific success of that endeavor - which was recently submitted as an NDA to the FDA - as well as the relationship we have established. Commenting on that relationship, William H. Carson, Vice President - Scientific Affairs of Bayer Consumer Care said, "Andrx has set the standard by which we now measure our development partners."

Andrx is engaged in the formulation and commercialization of oral controlled-release pharmaceuticals utilizing its proprietary drug delivery technologies, either directly or through collaborative arrangements. In its ANDA program, the Company is developing generic versions of selected high sales volume controlled-release brand name pharmaceuticals. In its NDA program, the Company is developing its own brand name formulations of certain existing drugs that it believes may be improved by the application of the Company's drug delivery technologies. The Company also markets and distributes pharmaceutical products manufactured by third parties and, through its Cybear, Inc. subsidiary, is developing internet-based software and applications for the healthcare industry.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

This release and additional information about Andrx Corporation

are also available on the Internet at: http://www.andrx.com